{
  "docId": "019de075-89b3-76e0-854f-751e522d63c5",
  "docSlug": "a1e66a21a5f72ac122dd8f79d63b40d9",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 39,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "Includes footnote regarding currency exchange rate for the option exercise payment.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-89b3-76e0-854f-751e522d63c5/6",
  "deckHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5",
  "deckJsonHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5.json",
  "deckAnchorHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.095,
        "w": 0.926,
        "x": 0.037,
        "y": 0.00117
      },
      "kind": "callout",
      "text": "Equillium receives upfront payment and full funding of itolizumab R&D in exchange for Ono exclusive option to purchase Equillium’s rights to itolizumab",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d56515d-636e-485f-806c-cadbd29ae956",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.13,
        "y": 0.00945
      },
      "kind": "disclaimer",
      "text": "*Option exercise payment of ¥5.0B is based in JPY and subject to currency exchange rate at the time of payment (USD amount above is based on the exchange rate as of August 8, 2023); milestone payments and R&D reimbursement are based in USD.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07277326-a7df-437a-9473-6afc4140f382",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.32,
        "x": 0.00625,
        "y": 0.00375
      },
      "kind": "image",
      "text": "ONO PHARMACEUTICAL CO.,LTD.",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74e2170d-c1ae-4fff-b03f-a50b32cdc155",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.33,
        "x": 0.00622,
        "y": 0.00575
      },
      "kind": "list",
      "text": "topline data from the EQUALISE study in lupus nephritis, and\ninterim data from the EQUATOR study in acute GVHD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "091e8e31-15c1-41b4-b657-e5e34f56f6b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.465,
        "x": 0.052,
        "y": 0.00555
      },
      "kind": "list",
      "text": "Equillium to continue conducting all itolizumab R&D\nOno to fund all R&D expenses from July 1, 2022 through the option period\nR&D budget approximately $8M per quarter",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56345a14-2177-4f78-9a56-9db25fafb8c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.335,
        "x": 0.052,
        "y": 0.008150000000000001
      },
      "kind": "list",
      "text": "Clinical • Regulatory • First sale",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0db4307-6e38-4e2e-a995-d3a343e4a960",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.225,
        "w": 0.499,
        "x": 0.052,
        "y": 0.00375
      },
      "kind": "table",
      "text": "Upfront payment: $26.4M\nOption exercise payment: $35.1M*\nMilestone payments: $101.4M\nTotal potential value: $162.9M",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08d5364b-8aa8-4a08-bc53-32a39b8d0d52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.783,
        "x": 0.037,
        "y": 0.078
      },
      "kind": "title",
      "text": "Ono Pharmaceutical: High Value Strategic Partnership",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edce4aee-0382-4d8b-96ab-e5a19778442d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "c171f210-c054-4a73-9bea-bf28f67a41d8",
      "evidence": "The slide presents a clear 'call to action' with 'Ono Pharmaceutical: High Value Strategic Partnership' as the title, and provides details about the partnership, including 'upfront payment' and 'milestone payments', which are typical components of an AIDA (Attention, Interest, Desire, Action) model.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "e5014b0a-2ea1-4c1d-aa62-8b23051676e0",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents Equillium's solution, including itolizumab and EQ101",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}